EI
EDVA

EAM Investors’s Endovia Health Sciences, Inc. EDVA Stock Holding History

EAM Investors’s Portfolio EDVA Stock Details EDVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,699
Closed -$772K – 341
2022
Q1 		$772K Buy
+1,699
New +$867K 0.14% 267

Other funds holding EDVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TF
TRH Financial North Liberty, Iowa $297M AUM 7.9% 1-Year Est. Return

EAM Investors's EDVA Position: Q2 2022 in Review

EAM Investors sold out of Endovia Health Sciences, Inc. (EDVA) in Q2 2022, closing a stake of 1,699 shares — an estimated $772K sold.

EAM Investors first reported a position in EDVA in Q1 2022 and held it in 1 quarter. The position peaked at $772K in Q1 2022. 22 funds tracked by Wall St. Rank hold EDVA as of Q2 2022.

  • EAM Investors reported no remaining Endovia Health Sciences, Inc. position as of Q2 2022 after selling out during the quarter.
  • EAM Investors sold 1,699 Endovia Health Sciences, Inc. shares in Q2 2022, an estimated $772K.
  • EAM Investors first reported a position in Endovia Health Sciences, Inc. in Q1 2022 and held it in 1 quarter.
  • EAM Investors's Endovia Health Sciences, Inc. position peaked at $772K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q2 2022.

Based on EAM Investors's 13F filing for Q2 2022, filed 12 Aug 2022.